Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 microg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high-risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study RESULTS: Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P < 0.006). The incidence of ocular disease progression was only 27% in patients treated with octreotide compared with 42% in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS: Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.
|
Authors | M B Grant, R N Mames, C Fitzgerald, K M Hazariwala, R Cooper-DeHoff, S Caballero, K S Estes |
Journal | Diabetes care
(Diabetes Care)
Vol. 23
Issue 4
Pg. 504-9
(Apr 2000)
ISSN: 0149-5992 [Print] United States |
PMID | 10857943
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Glycated Hemoglobin A
- Vasoconstrictor Agents
- Insulin-Like Growth Factor I
- Octreotide
|
Topics |
- Diabetes Mellitus, Type 1
(physiopathology)
- Diabetes Mellitus, Type 2
(physiopathology)
- Diabetic Retinopathy
(drug therapy, physiopathology)
- Disease Progression
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Infusions, Intravenous
- Injections, Subcutaneous
- Insulin-Like Growth Factor I
(metabolism)
- Male
- Octreotide
(administration & dosage, therapeutic use)
- Pilot Projects
- Vasoconstrictor Agents
(administration & dosage, therapeutic use)
|